Omeros (NASDAQ:OMER) Shares Down 5.6% – Should You Sell?

Omeros Corporation (NASDAQ:OMER)’s stock price traded down 5.6% during trading on Tuesday . The company traded as low as $8.48 and last traded at $8.57. 1,679,579 shares traded hands during mid-day trading, an increase of 3% from the average session volume of 1,632,897 shares. The stock had previously closed at $9.08.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Wall Street Zen lowered Omeros from a “hold” rating to a “sell” rating in a research note on Saturday. HC Wainwright increased their price objective on shares of Omeros from $9.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, October 15th. D. Boral Capital reissued a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Friday. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Wednesday, October 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.67.

Omeros Trading Down 6.4%

The stock’s 50-day moving average is $5.88 and its 200-day moving average is $4.57. The stock has a market cap of $578.34 million, a price-to-earnings ratio of -4.06 and a beta of 2.40.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.39. On average, equities analysts predict that Omeros Corporation will post -3.09 earnings per share for the current fiscal year.

Institutional Trading of Omeros

A number of institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in shares of Omeros by 2.2% during the first quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company’s stock worth $1,242,000 after purchasing an additional 3,321 shares in the last quarter. Harbour Investments Inc. boosted its stake in shares of Omeros by 51.9% in the first quarter. Harbour Investments Inc. now owns 9,218 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,149 shares during the period. Vanguard Group Inc. grew its stake in shares of Omeros by 3.0% during the first quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company’s stock valued at $26,610,000 after acquiring an additional 95,599 shares in the last quarter. Deutsche Bank AG boosted its holdings in Omeros by 4.9% in the first quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company’s stock valued at $345,000 after purchasing an additional 1,973 shares during the last quarter. Finally, Invesco Ltd. grew its stake in Omeros by 169.1% during the 1st quarter. Invesco Ltd. now owns 87,044 shares of the biopharmaceutical company’s stock valued at $716,000 after purchasing an additional 54,696 shares in the last quarter. 48.79% of the stock is owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.